Overview
Photopharmics develops the Celeste light therapy device, a precisely calibrated intrinsically photosensitive retinal ganglion cell (ipRGC) stimulator designed to treat Parkinson's disease non-motor symptoms.
More in Neuromodulation
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
⚡ Neuromodulation
Location
Salt Lake City, UT, USA
Funding
Series A · $15M
Website
www.photopharmics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →